中文

← All funding rounds

Undecimal Bio

EuropeDrug discoveryCambridge, UK, with an office in Tel Aviv, United KingdomPrivate

Website · undecimalbio.com ↗

Looks for small-molecule conjugates that carry siRNA drugs into tissues beyond the liver: it screens combinatorial libraries of candidate ligands in cells that report productive delivery, and trains models on the screens. Its first programmes are in kidney and blood-vessel disease.

Disclosed total$18M
Rounds on record1
Latest round$18MSeed · 2026-10-13
Last stated valuationNone stated
Investors named7
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date$18M
Closed round

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2026-10-13Seed
    Round

    $18M

    For: developing the DELiveri platform, advancing its renovascular programmes, and growing the team at its labs in the Cancer Research UK Cambridge Institute

    Models and platformHiring

    The release calls the round oversubscribed and co-led by the two firms, gives no valuation, and says the board takes representatives of 4BIO Capital, IQ Capital and Harel Technologies with the two co-founders, and Verve Ventures as observer. Read in the Business Wire copy on FinancialContent; EU-Startups reported it as EUR 16M.

    Co-lead · 4BIO CapitalCo-lead · IQ CapitalVerve VenturesHarel TechEntree CapitalKerna VenturesSaras Capital

    Announced by the company · businesswire.com ↗On the timeline →

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.